GPCR-autoantibodies in chronic heart failure

Area of Science:

• Cardiology
• Immunology
• Internal Medicine

Background:

• Chronic heart failure (CHF) is a complex syndrome with diverse etiologies.
• Ischemic heart disease accounts for over 60% of CHF cases, while non-ischemic causes, including myocardial inflammation, comprise about 30%.
• Patients with non-ischemic CHF often exhibit dysregulated immune responses, leading to autoantibodies against cardiac antigens.

Purpose of the Study:

• To review the pathophysiological role of G-protein coupled receptor (GPCR) autoreactivity in chronic heart failure (CHF).
• To summarize evidence from pre-clinical, clinical, and epidemiological studies on the CHF-inducing potential of GPCR autoantibodies.
• To discuss novel therapeutic strategies for GPCR autoantibody-associated CHF.

Main Methods:

• Review of existing literature on GPCR autoantibodies and their association with chronic heart failure.
• Analysis of pre-clinical, clinical, and epidemiological data.
• Synthesis of current knowledge on the pathogenesis and treatment of GPCR autoantibody-mediated CHF.

Main Results:

• Non-ischemic myocardial damage progresses to CHF, particularly when associated with autoantibodies against critical myocyte membrane proteins like GPCRs.
• Virus persistence in the myocardium is another factor contributing to CHF progression in non-ischemic cases.
• GPCR autoantibodies are implicated in the pathogenesis of CHF, especially in non-ischemic forms.

Conclusions:

• GPCR autoantibodies play a significant role in the development and progression of non-ischemic chronic heart failure.
• Understanding GPCR-autoreactivity opens avenues for novel therapeutic interventions in specific CHF populations.
• Further research is warranted to fully elucidate the mechanisms and therapeutic potential of targeting GPCR autoantibodies in CHF.